Literature DB >> 30759363

Plausible biochemical mechanisms of chemotherapy-induced cognitive impairment ("chemobrain"), a condition that significantly impairs the quality of life of many cancer survivors.

Xiaojia Ren1, Diana Boriero2, Luksana Chaiswing3, Subbarao Bondada4, Daret K St Clair3, D Allan Butterfield5.   

Abstract

Increasing numbers of cancer patients survive and live longer than five years after therapy, but very often side effects of cancer treatment arise at same time. One of the side effects, chemotherapy-induced cognitive impairment (CICI), also called "chemobrain" or "chemofog" by patients, brings enormous challenges to cancer survivors following successful chemotherapeutic treatment. Decreased abilities of learning, memory, attention, executive function and processing speed in cancer survivors with CICI, are some of the challenges that greatly impair survivors' quality of life. The molecular mechanisms of CICI involve very complicated processes, which have been the subject of investigation over the past decades. Many mechanistic candidates have been studied including disruption of the blood-brain barrier (BBB), DNA damage, telomere shortening, oxidative stress and associated inflammatory response, gene polymorphism of neural repair, altered neurotransmission, and hormone changes. Oxidative stress is considered as a vital mechanism, since over 50% of FDA-approved anti-cancer drugs can generate reactive oxygen species (ROS) or reactive nitrogen species (RNS), which lead to neuronal death. In this review paper, we discuss these important candidate mechanisms, in particular oxidative stress and the cytokine, TNF-alpha and their potential roles in CICI.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Blood-brain barrier; Chemotherapy-induced cognitive impairment; Mitochondrial dysfunction; Oxidative damage; TNF-alpha

Mesh:

Substances:

Year:  2019        PMID: 30759363      PMCID: PMC6502692          DOI: 10.1016/j.bbadis.2019.02.007

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Basis Dis        ISSN: 0925-4439            Impact factor:   5.187


  150 in total

Review 1.  Polymorphisms in DNA repair genes and associations with cancer risk.

Authors:  Ellen L Goode; Cornelia M Ulrich; John D Potter
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-12       Impact factor: 4.254

Review 2.  Candidate mechanisms for chemotherapy-induced cognitive changes.

Authors:  Tim A Ahles; Andrew J Saykin
Journal:  Nat Rev Cancer       Date:  2007-03       Impact factor: 60.716

3.  Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning.

Authors:  Sabine Deprez; Frederic Amant; Ann Smeets; Ronald Peeters; Alexander Leemans; Wim Van Hecke; Judith S Verhoeven; Marie-Rose Christiaens; Joris Vandenberghe; Mathieu Vandenbulcke; Stefan Sunaert
Journal:  J Clin Oncol       Date:  2011-12-19       Impact factor: 44.544

Review 4.  Redox Paradox: A Novel Approach to Therapeutics-Resistant Cancer.

Authors:  Luksana Chaiswing; William H St Clair; Daret K St Clair
Journal:  Antioxid Redox Signal       Date:  2018-02-21       Impact factor: 8.401

5.  Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study.

Authors:  Brenna C McDonald; Susan K Conroy; Tim A Ahles; John D West; Andrew J Saykin
Journal:  Breast Cancer Res Treat       Date:  2010-08-06       Impact factor: 4.872

6.  Increase in Mrp1 expression and 4-hydroxy-2-nonenal adduction in heart tissue of Adriamycin-treated C57BL/6 mice.

Authors:  Paiboon Jungsuwadee; Marsha P Cole; Rukhsana Sultana; Gurujaj Joshi; Jitbanjong Tangpong; D Allan Butterfield; Daret K St Clair; Mary Vore
Journal:  Mol Cancer Ther       Date:  2006-11       Impact factor: 6.261

Review 7.  Cytokine-mediated blood brain barrier disruption as a conduit for cancer/chemotherapy-associated neurotoxicity and cognitive dysfunction.

Authors:  Hannah R Wardill; Kimberley A Mander; Ysabella Z A Van Sebille; Rachel J Gibson; Richard M Logan; Joanne M Bowen; Stephen T Sonis
Journal:  Int J Cancer       Date:  2016-07-15       Impact factor: 7.396

Review 8.  Brain peroxisomes.

Authors:  D Trompier; A Vejux; A Zarrouk; C Gondcaille; F Geillon; T Nury; S Savary; G Lizard
Journal:  Biochimie       Date:  2013-09-21       Impact factor: 4.079

9.  The effects of hormone therapy on cognition in breast cancer.

Authors:  Valerie Shilling; Valerie Jenkins; Lesley Fallowfield; Tony Howell
Journal:  J Steroid Biochem Mol Biol       Date:  2003-09       Impact factor: 4.292

10.  Altered DNA base excision repair profile in brain tissue and blood in Alzheimer's disease.

Authors:  Meryl S Lillenes; Alberto Rabano; Mari Støen; Tahira Riaz; Dorna Misaghian; Linda Møllersen; Ying Esbensen; Clara-Cecilie Günther; Per Selnes; Vidar T V Stenset; Tormod Fladby; Tone Tønjum
Journal:  Mol Brain       Date:  2016-05-28       Impact factor: 4.041

View more
  15 in total

1.  CD4+CD126low/- Foxp3+ Cell Population Represents a Superior Subset of Regulatory T Cells in Treating Autoimmune Diseases.

Authors:  Ye Chen; Zhenjian Xu; Rongzhen Liang; Julie Wang; Anping Xu; Ning Na; Bin Li; Ruoning Wang; Miller Joseph; Nancy Olsen; Willa Hsueh; Song Guo Zheng
Journal:  Mol Ther       Date:  2020-07-21       Impact factor: 11.454

2.  Changes in Attentional Function in Patients From Before Through 12 Months After Breast Cancer Surgery.

Authors:  Carmen Kohler; Ming Chang; Yu-Yin Allemann-Su; Marcus Vetter; Miyeon Jung; Misook Jung; Yvette Conley; Steven Paul; Kord M Kober; Bruce A Cooper; Betty Smoot; Jon D Levine; Christine Miaskowski; Maria C Katapodi
Journal:  J Pain Symptom Manage       Date:  2020-01-15       Impact factor: 3.612

3.  Childhood Neurotoxicity and Brain Resilience to Adverse Events during Adulthood.

Authors:  AnnaLynn M Williams; Yin Ting Cheung; Geehong Hyun; Wei Liu; Kirsten K Ness; Matthew J Ehrhardt; Daniel A Mulrooney; Nickhill Bhakta; Pia Banerjee; Tara M Brinkman; Daniel M Green; Wassim Chemaitilly; I-Chan Huang; Deokumar Srivastava; Melissa M Hudson; Leslie L Robison; Kevin R Krull
Journal:  Ann Neurol       Date:  2020-12-31       Impact factor: 10.422

4.  Pharmacological signatures of the reduced incidence and the progression of cognitive decline in ageing populations suggest the protective role of beneficial polypharmacy.

Authors:  Anatoly L Mayburd; Mathilda Koivogui; Ancha Baranova
Journal:  PLoS One       Date:  2019-11-06       Impact factor: 3.240

Review 5.  "Amyloid-beta accumulation cycle" as a prevention and/or therapy target for Alzheimer's disease.

Authors:  Chinthalapally V Rao; Adam S Asch; Daniel J J Carr; Hiroshi Y Yamada
Journal:  Aging Cell       Date:  2020-01-25       Impact factor: 9.304

6.  Clinical impact of melatonin on breast cancer patients undergoing chemotherapy; effects on cognition, sleep and depressive symptoms: A randomized, double-blind, placebo-controlled trial.

Authors:  Ana Claudia Souza Palmer; Maxciel Zortea; Andressa Souza; Vinicius Santos; Jorge Villanova Biazús; Iraci L S Torres; Felipe Fregni; Wolnei Caumo
Journal:  PLoS One       Date:  2020-04-17       Impact factor: 3.240

7.  Nasal administration of mitochondria reverses chemotherapy-induced cognitive deficits.

Authors:  Jenolyn F Alexander; Alexandre V Seua; Luis D Arroyo; Pradipta R Ray; Andi Wangzhou; Laura Heiβ-Lückemann; Manfred Schedlowski; Theodore J Price; Annemieke Kavelaars; Cobi J Heijnen
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

Review 8.  Ocoxin as a complement to first line treatments in cancer.

Authors:  Aitor Benedicto; Eduardo Sanz; Joana Márquez
Journal:  Int J Med Sci       Date:  2021-01-01       Impact factor: 3.738

Review 9.  Targeting strategies for oxaliplatin-induced peripheral neuropathy: clinical syndrome, molecular basis, and drug development.

Authors:  Yang Yang; Bing Zhao; Xuejiao Gao; Jinbing Sun; Juan Ye; Jun Li; Peng Cao
Journal:  J Exp Clin Cancer Res       Date:  2021-10-22

Review 10.  The Promise of Nutrient-Derived Bioactive Compounds and Dietary Components to Ameliorate Symptoms of Chemotherapy-Related Cognitive Impairment in Breast Cancer Survivors.

Authors:  Nagi B Kumar
Journal:  Curr Treat Options Oncol       Date:  2021-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.